Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Jun 2025 value amounting to -$1.7 million.

  • Day One Biopharmaceuticals' Capital Expenditures fell 103.05% to -$1.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$34.7 million, marking a year-over-year decrease of 162.83%. This contributed to the annual value of $20.0 million for FY2024, which is 8828.57% up from last year.
  • Day One Biopharmaceuticals' Capital Expenditures amounted to -$1.7 million in Q2 2025, which was down 184.00% from $2.0 million recorded in Q1 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Capital Expenditures peaked at $55.0 million during Q2 2024, and registered a low of -$54.2 million during Q3 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $41,000 (2023), whereas its average is $2.3 million.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Capital Expenditures showed a top increase of 240,525.00% in 2024 and a maximum decrease of 132,417.07% in 2024.
  • Quarterly analysis of 4 years shows Day One Biopharmaceuticals' Capital Expenditures stood at $4,000 in 2022, then surged by 925.00% to $8,000 in 2023, then soared by 240,525.00% to $19.2 million in 2024, then tumbled by 103.05% to -$1.7 million in 2025.
  • Its Capital Expenditures was -$1.7 million in Q2 2025, compared to $2.0 million in Q1 2025 and $19.2 million in Q4 2024.